Results 61 to 70 of about 5,649 (188)

Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

BMJ Open
Objective The Canadian Real-world Evidence for Value in Cancer (CanREValue) Collaboration was established in response to growing interest in using real-world evidence (RWE) to support health technology assessment (HTA).
Stuart Peacock, Avram Denburg, Petros Pechlivanoglou, Wanrudee Isaranuwatchai, Claire de Oliveira, Yvonne Bombard, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Carole Chambers, Maureen Trudeau, Craig C Earle, Kelvin Kar-Wing Chan, Winson Y Cheung, Pam Takhar, William K Evans, Caroline Muñoz, Erica Craig, Marc Geirnaert, Tarry Ahuja, Riaz Alvi   +23 more
doaj   +1 more source

Creating and using real-world evidence to answer questions about clinical effectiveness

Journal of Innovation in Health Informatics, 2015
New forms of evidence are needed to complement evidence generated from randomised controlled trials (RCTs). Real-World Evidence (RWE) is a potential new form of evidence, but remains undefined.This paper sets to fill that gap by defining RWE as the ...
Simon de Lusignan, Laura Crawford, Neil Munro   +2 more
doaj   +1 more source

Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study evaluated long‐term cost‐effectiveness of automated insulin delivery (AID) systems versus multiple daily injections (MDI) + CGM in children with type 1 diabetes (T1D), adults with T1D and insulin‐treated individuals with type 2 diabetes (T2D) across Denmark, Finland, Norway and Sweden.
Johan Jendle, Kirsten Nørgaard, Elina Pimiä, Heiko Bratke, Aesha Khan Mirón, Maria‐Eleni Syleouni   +5 more
wiley   +1 more source

Real‐World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis

European Journal of Haematology, EarlyView.
ABSTRACT Objective This systematic review and meta‐analysis aimed to evaluate the risk of thromboembolic events and assess the overall safety and effectiveness of avatrombopag in adult patients with immune thrombocytopenia using real‐world evidence. Methods A systematic search was conducted following the PRISMA 2020 guidelines.
M. L. Lozano, D. Valcarcel
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Expert survey on real‐world data utilization and real‐world evidence generation for regulatory decision‐making in drug lifecycle in Korea

Clinical and Translational Science
As the importance of utilizing real‐world data (RWD)/real‐world evidence (RWE) for supporting regulatory scientific decision‐making continues to grow, experiences and inputs from experts become crucial for developing a systematic and practice‐oriented ...
Hankil Lee, Hyeon‐Soo Ahn, Sol Kwon, Hye‐Young Kang, Euna Han   +4 more
doaj   +1 more source

Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance

Journal of Market Access & Health Policy
Background: Real-world evidence (RWE) can reinforce clinical trial evidence in health technology assessment (HTA). Objectives: Review HTA bodies’ (HTAbs) requirements for RWE, real uses, and acceptance across seven countries (Brazil, Canada, France ...
Katia Thokagevistk, Céline Coppo, Laetitia Rey, Amanda Carelli, Veronica Díez, Sarah Vaselenak, Liana Oliveira, Ajay Patel, Emilia Sicari, Teresa Ramos, Susanne Schach, Erika Schirghuber, Alex Simpson, Remy Choquet, Katell Le Lay   +14 more
doaj   +1 more source

PNS219 RWE ALGORITHMS - THE BUILDING BLOCKS OF RWE QUALITY [PDF]

Value in Health, 2020
J. Murray, J. Beyrer, H. Abedtash, K. Hornbuckle   +3 more
openaire   +1 more source

The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl, Claudia Zeidler, Joyce Loewenthal, Svenja Royeck, Matthias Augustin, Robert Bissonnette, Sarina Elmariah, Brian S. Kim, Laurent Misery, Hiroyuki Murota, Hong Liang Tey, Elke Weisshaar, Gil Yosipovitch, Franz J. Legat, Adam Reich, Martin Metz, Sonja Ständer   +16 more
wiley   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source